Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer.

Anticancer research - 1 Sept 2020

Kobayashi Kunihiko, Kaira Kyoichi, Kagamu Hiroshi

Abstract excerpt

BACKGROUND/AIM: Experimental studies have shown that celecoxib is related to the downregulation of Tregs and an increase in the therapeutic efficacy of PD-1 inhibitors; however, such effect has not been shown in human cancers. Our report confirmed the synergistic effect of celecoxib with a PD-1 inhibitor. CASE REPORT: A 57-year-old male with advanced pulmonary adenocarcinoma was treated with nivolumab monotherapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Cyclooxygenase 2 Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Drug Synergism

Share to Immunomodulation

Share to Programmed Cell Death 1 Receptor

Share to Radiography, Thoracic

Share to T-Lymphocytes

Source

Identifiers

PMID: 32878822
DOI: 10.21873/anticanres.14537

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer.PMID 32878822Read ↗

Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD-L1: A case report.Semantic proximity Read ↗

A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.Semantic proximity Read ↗

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report.Semantic proximity Read ↗

Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.Semantic proximity Read ↗

Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.Semantic proximity Read ↗

Efficacy and Safety of PD-1/PD-L1 plus CTLA-4 antibodies +/− Other Therapies in Lung Cancer: A Systematic Review and Meta-AnalysisSemantic proximity Read ↗

Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.Semantic proximity Read ↗

Reduction of pericardial effusion in advanced non-small cell lung cancer patients with KRAS, TP53, and MET mutation treated with nivolumab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.